Stoke Therapeutics, Inc. STOK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.23M+344% | $1.4M-86.8% | $10.63M-23.1% | $13.82M-91.3% | $158.57M+601% | ||
| $39.67M-4.8% | $41.7M+10.6% | $37.7M+45.8% | $25.86M-20.9% | $32.68M+39.5% | ||
| $19.97M-5.5% | $21.15M+31.9% | $16.03M+5.0% | $15.26M+4.2% | $14.65M+14.1% | ||
| $59.65M-5.1% | $62.84M+17.0% | $53.72M+30.7% | $41.12M-13.1% | $47.33M+30.5% | ||
| $59.65M-5.1% | $62.84M+17.0% | $53.72M+30.7% | $41.12M-13.1% | $47.33M+30.5% | ||
| -$53.42M+13.1% | -$61.44M-42.6% | -$43.09M-57.8% | -$27.3M-125% | $111.24M+915% | ||
| -857.6%+3,525pp | -4,382.2%-3,977pp | -405.3%-208pp | -197.6%-268pp | 70.2%+131pp | ||
| $3.4M-6.0% | $3.62M+4.4% | $3.46M-8.6% | $3.79M+31.2% | $2.89M-2.7% | ||
| $3.42M-2.6% | $3.51M+1.1% | $3.47M-9.2% | $3.82M+30.9% | $2.92M-8.0% | ||
| -$50M— | —— | -$39.63M-68.7% | -$23.48M-121% | $114.16M— | ||
| -$0— | —— | -$1.28M— | $0-100% | $1.28M— | ||
| -$50M+13.7% | -$57.93M-51.1% | -$38.35M-63.3% | -$23.48M-121% | $112.88M+1,177% | ||
| -802.7%+3,329pp | -4,132.2%-3,772pp | -360.7%-191pp | -170%-241pp | 71.2%+118pp | ||
| -$0.79+18.6% | -$0.97-49.2% | -$0.65-62.5% | -$0.40-121% | $1.90+1,218% | ||
| -$0.79+21.0% | -$1.00-53.8% | -$0.65-62.5% | -$0.40-121% | $1.95+1,247% | ||
| 63.1M+6.5% | 59.2M+1.0% | 58.6M+0.4% | 58.4M-1.8% | 59.4M+10.0% | ||
| 63.1M+6.5% | 59.2M+1.0% | 58.6M+0.4% | 58.4M+0.8% | 57.9M+7.1% | ||
| $3.4M-6.0% | $3.62M+4.4% | $3.46M-8.6% | $3.79M+31.2% | $2.89M-2.7% | ||
| -$50.66M+12.4% | -$57.84M-52.2% | -$38M-63.2% | -$23.28M-121% | $112.93M+1,146% | ||
| -$658K-778% | $97K-72.3% | $350K+75.0% | $200K+326% | $47K+115% | ||
| -$658K-778% | $97K-72.3% | $350K+75.0% | $200K+326% | $47K+115% | ||
| $18K+116% | -$110K-3,767% | $3K-89.3% | $28K0.0% | $28K— | ||
| -$53.42M+13.1% | -$61.44M-42.6% | -$43.09M-57.8% | -$27.3M-125% | $111.24M+915% | ||
| -$52.98M+13.2% | -$61.03M-43.1% | -$42.65M-58.8% | -$26.85M-124% | $111.72M+951% | ||
| -$52.98M+13.2% | -$61.03M-43.1% | -$42.65M-58.8% | -$26.85M-124% | $111.72M+951% | ||
| -850.5%+3,503pp | -4,353.4%-3,952pp | -401.1%-207pp | -194.4%-265pp | 70.5%+129pp | ||
| -$53.42M+13.1% | -$61.44M-42.6% | -$43.09M-57.8% | -$27.3M-125% | $111.24M+915% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Stoke Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.